QureBio Closes Nearly CNY 100M Series C1 Financing

QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines

SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel antibody therapeutics.

QureBio Closes Nearly CNY 100M Series C1 Financing

QureBio, a Shanghai, China-based company developing bispecific and multispecific antibody and protein therapeutics, raised nearly CNY 100M (approx. $14M) in Series C1 funding. The round was led by Efung Capital. The company intends to use the funds to accelerate its clinical trials and advance its pipeline of new antibody therapeutics. Founded in 2017, Qure Biotechnology […] The post QureBio Closes Nearly CNY 100M Series C1 Financing appeared fi…